Dr. McCallum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
490 Lapp Road
Malvern, PA 19355
Summary
- Dr. Stewart McCallum is a urology specialist based in Malvern, PA. He completed his medical studies in 1992 at the University of Toronto Faculty of Medicine, followed by a residency in Urology at the University of Toronto and a Fellowship at New York Presbyterian Hospital (Cornell Campus) from 1992 to 1998. He is a consultant chief medical officer with expertise in translational medicine. He is highly experienced at all stages of clinical development, from first-in-human clinical trials through phase III to file approval and launch across various indications. He is a Fellow of the American College of Surgeons and a member of the Royal College of Surgeons Canada.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1997 - 1998
University of TorontoResidency, Urology, 1992 - 1997
University of Toronto Faculty of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1998 - 2025- American Board of Urology Urology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Evaluation of N1539 Following Bunionectomy Surgery Start of enrollment: 2016 Jan 01
- Evaluation of N1539 Following Major Surgery Start of enrollment: 2016 Mar 01
- Evaluation of Preoperative N1539 in Colorectal Surgery Start of enrollment: 2017 Oct 24
- Join now to see all
Publications & Presentations
PubMed
- 52 citationsA Randomised Trial Evaluating the Effects of the TRPV1 Antagonist SB705498 on Pruritus Induced by Histamine, and Cowhage Challenge in Healthy VolunteersRachel A. Gibson, Jon Robertson, Harshna Mistry, Stewart W. McCallum, Disala Fernando
Plos One. 2014-07-21 - 153 citationsA Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2Joseph Paul Eder, Geoffrey I. Shapiro, Leonard Joseph Appleman, Andrew X. Zhu, Dale Miles
Clinical Cancer Research. 2010-07-01 - 7 citationsSafety and Efficacy of Perioperative Intravenous Meloxicam for Moderate-to-Severe Pain Management in Total Knee Arthroplasty: A Randomized Clinical Trial.Richard D Berkowitz, Richard Steinfeld, Alexander P. Sah, Randall J Mack, Stewart W. McCallum
Pain Medicine. 2021-06-04
Press Mentions
Baudax Bio Announces Publication of Phase IIIb Data on Preoperative Administration of ANJESO® in Patients Undergoing Total Knee Arthroplasty (TKA) in Pain MedicineApril 26th, 2021- Baudax Bio Announces Publication of ANJESO® Network Meta-Analysis in the Peer-Reviewed Journal BMC AnesthesiologyNovember 20th, 2020
- Baudax Bio Announces Presentation of New Phase IIIb ANJESO® Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific MeetingJuly 30th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
